Indacaterol Novartis/skyePharma.
Copyright policy )Indacaterol Novartis/skyePharma.
In collaboration with SkyePharma, Novartis is developing a multidose dry powder inhaler formulation of indacaterol, a long-acting beta2 agonist and bronchodilator, for the potential treatment of asthma and chronic obstructive pulmonary disease. In January 2006, Novartis expected phase III clinical trials to start in early 2006, with submission planned for 2007.
- NHS Grampian United Kingdom
- Aberdeen Royal Infirmary United Kingdom
Drug Evaluation, Preclinical, Adrenergic beta-Agonists, Quinolones, Asthma, Bronchodilator Agents, Patents as Topic, Pulmonary Disease, Chronic Obstructive, Administration, Inhalation, Indans, Animals, Humans, Randomized Controlled Trials as Topic
Drug Evaluation, Preclinical, Adrenergic beta-Agonists, Quinolones, Asthma, Bronchodilator Agents, Patents as Topic, Pulmonary Disease, Chronic Obstructive, Administration, Inhalation, Indans, Animals, Humans, Randomized Controlled Trials as Topic
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).7 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Average influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Average impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 10%
Citations provided by BIP!Popularity provided by BIP!